Latest Conference Articles

Preliminary data from the SPARTAN study were presented at ASN Kidney Week 2023, demonstrating sparsentan’s impact on proteinuria and total body water over time.

Disparities in nephrology were at the forefront of multiple sessions, presentations, and conversations at ASN Kidney Week 2023.

Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.

Results called attention to a greater risk of hospitalization among patients with CKD who exhibited depressive symptoms, regardless of treatment with dialysis.

Presented at AAO 2023, new data show dual Ang-2/VEGF-A inhibition with faricimab improved pigment epithelial detachment outcomes versus aflibercept.

Data presented at ASN Kidney Week 2023 highlighted the patient-reported difficulty of implementing physician-recommended lifestyle changes but noted significant impacts on physical health, mental health, and overall quality of life when done successfully.

In a pooled subcohort analysis of YOSEMITE and RHINE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.

At ASN Kidney Week 2023, we collected perspectives from 10 key opinion leaders in nephrology on what they see as the most significant news in their specialty from the past year.

Results presented at ASN Kidney Week 2023 highlighted the importance of eGFR and albuminuria measurements for identifying risk of major adverse kidney disease events.

Presented at AAO 2023, Russell Van Gelder, MD, PhD, discussed Abacus study and how KIO-301 targets low vision and end stage retinitis pigmentosa with visual acuity of light perception.

Two studies presented at AAO demonstrate that low dose atropine is associated with slowing myopia progression, but another study finds that this is not true. Thus, there are mixed results on this relationship.

Presented at AAO 2023, first-time results suggest home OCT may have a significant effect on treatment burden in the management of nAMD.

First-year results from ALTITUDE suggest RGX-314 was well-tolerated and provided meaningful improvements in disease severity at dose levels 1 and 2.

The study, presented at ASN Kidney Week 2023, sought to assess the impact of sociodemographic stress on outcomes in home dialysis among patients with ESRD.

Patrick Rossignol, MD, PhD, provides additional perspective on the results of the ALCHEMIST trial from Kidney Week 2023.

Food insecurity was associated with more missed appointments and fluid or electrolyte-related hospitalizations among patients on hemodialysis, especially those under 55 years of age.

Joanthan Barratt, MD, discusses the results of a RaDaR analysis aimed at examining trends in time-averaged proteinuria and eGFR slope in patients with IgA nephropathy.

Findings presented at ASN Kidney Week 2023 highlighted an association between distance to the transplant center and increased clinic cancellations.

Patients who are female, in minority groups (particularly, Black or Asian), a visual acuity outside of the <20/40 to 20/200 range, and who are >70 years old receive less treatment.

On the floor at AAO 2023, host Veeral Sheth, MD, discusses UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.

Michelle Rheault, MD, provides additional perspective on the results of the DUPLEX trial, which examined sparsentan in patients with FSGS.

Presented at AAO 2023, new 3-year data from the GALE extension study shows increasing treatment effects over time with pegcetacoplan injection for geographic atrophy.

Aflibercept 8 mg treatment did well with maintaining patients, according to a presentation focusing on the PULSAR study.

In a presentation at AAO 2023, Tsang discussed topline data from the phase 2 trial on MCO-010 optogenetic therapy for vision loss in Stargardt Disease.

Data presented at ASN Kidney Week 2023 suggested male kidney donors recover greater kidney function than females after donation.

ARCHER study demonstrated that the antibody ANX007 was time and dose dependent, robust, and not dependent on lesion growth.

Data for a pair of studies presented at Kidney Week 2023 provide an overview of the effects of eGFR and how this might translate to potential long-term benefit in patients IgA nephropathy.

We sat down with Maya Clark-Cutaia, RN, MSN, PhD, assistant professor of nursing at New York University Rory Meyers College of Nursing to discuss disparities in the kidney transplantation process and how they should be addressed in future efforts.